TTK Healthcare

Why is TTK Healthcare Ltd. falling/rising?

As of 27-Aug, TTK Healthcare Ltd. is facing a stock price decline to 1,080.60, down 1.18%, and has underperformed its sector. Despite a year-to-date gain of 4.34%, the stock has shown mixed results with a recent downward trend and negative sentiment.

As of 27-Aug, TTK Healthcare Ltd. is experiencing a decline in its stock price, currently at 1,080.60, which reflects a change of -12.95 (-1.18%). The stock has been underperforming compared to the broader market, as indicated by its performance today, where it underperformed its sector by -1.96%. Additionally, the stock has been on a consecutive downward trend, losing -2.59% over the last three days.<BR><BR>In terms of longer-term performance, TTK Healthcare has shown mixed results. Over the past week, it has gained slightly by +0.09%, while it has seen a decline of -0.19% over the past month. Year-to-date, however, the stock has performed relatively well with a gain of +4.34%, contrasting with a significant decline of -9.72% in the Sensex. Despite this, the stock has underperformed over the past year, with a decrease of -5.31%, compared to a smaller decline of -4.77% in the Sensex.<BR><BR>The stock's moving averages indicate that it is currently higher than the 50-day, 100-day, and 200-day moving averages, but lower than the 5-day and 20-day moving averages, suggesting some short-term volatility. Furthermore, while there has been a rise in investor participation, with delivery volume increasing by 19.78% against the 5-day average, the overall sentiment appears negative due to the recent price declines and underperformance relative to the sector.

Which are the latest news on TTK Healthcare?

Should I buy, sell or hold TTK Healthcare Ltd.?

Who are in the management team of TTK Healthcare?

The management team of TTK Healthcare includes T T Raghunathan (Executive Chairman), S Kalyanaraman (Whole Time Director & Secretary), and several non-executive directors, including independent members like Vandana R Walvekar and Girish Rao. This team is responsible for the company's strategic direction and management.

The management team of TTK Healthcare includes the following members:<BR><BR>1. **T T Raghunathan** - Executive Chairman<BR>2. **R K Tulshan** - Non-Executive & Non-Independent Director<BR>3. **K Shankaran** - Non-Executive & Non-Independent Director<BR>4. **S Kalyanaraman** - Whole Time Director & Secretary<BR>5. **Vandana R Walvekar** - Non-Executive & Independent Director<BR>6. **Girish Rao** - Non-Executive & Independent Director<BR>7. **S Balasubramanian** - Non-Executive & Independent Director<BR>8. **N Ramesh Rajan** - Non-Executive & Independent Director<BR>9. **V Ranganathan** - Non-Executive & Independent Director<BR>10. **T T Mukund** - Director<BR><BR>This team oversees the strategic direction and management of the company. If you have any more questions about TTK Healthcare or its operations, feel free to ask!

What does TTK Healthcare do?

TTK Healthcare Ltd. is a micro-cap company focused on pharmaceuticals for animal welfare, consumer products, medical devices, and foods. As of June 2026, it reported net sales of 258 Cr and a net profit of 21 Cr, with a market cap of INR 1,628 Cr.

Overview:<BR>TTK Healthcare Ltd. operates in the diversified industry, focusing on pharmaceuticals for animal welfare, consumer products, medical devices, foods, and protective devices, and is categorized as a micro-cap company.<BR><BR>History:<BR>TTK Healthcare Limited was incorporated in May 1958 as Orient Pharma and was later renamed TTK Pharma in November 1981. The latest quarterly results reported net sales and profit for June 2026.<BR><BR>Financial Snapshot:<BR>- Net Sales: 258 Cr (Quarterly Results - Jun 2026)<BR>- Net Profit: 21 Cr (Quarterly Results - Jun 2026)<BR>- Market cap: INR 1,628 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>- P/E: 21.00<BR>- Industry P/E: 37<BR>- Dividend Yield: 0.91%<BR>- Debt Equity: -0.55<BR>- Return on Equity: 6.91%<BR>- Price to Book: 1.40<BR><BR>Contact Details:<BR>Address: 6 Cathedral Road, Chennai Tamil Nadu: 600086 <BR>Tel: 91-44-28116106-28116110 <BR>Email: info@ttkhealthcare.com <BR>Website: http://www.ttkhealthcare.com

Who are the peers of the TTK Healthcare?

TTK Healthcare's peers include 3M India, DCM Shriram, Swan Corp, and others. Notably, 3M India shows excellent management and growth, while TTK Healthcare has a 1-year return of -0.14%, better than DCM Shriram's -24.04%.

Peers: The peers of TTK Healthcare are 3M India, DCM Shriram, Swan Corp, Sindhu Trade, Balmer Lawrie, Dhunseri Vent., Empire Inds., Panth Infinity, and Aspinwall & Co.<BR><BR>Quality Snapshot: Excellent management risk is observed at 3M India and DCM Shriram, while Average management risk is found at Swan Corp, Balmer Lawrie, Dhunseri Vent., Empire Inds., Panth Infinity, and Aspinwall & Co, and the rest. Good growth is seen at 3M India and Panth Infinity, while Below Average growth is noted at DCM Shriram, Swan Corp, Sindhu Trade, Balmer Lawrie, TTK Healthcare, Dhunseri Vent., and the rest. Excellent capital structure is present at 3M India, DCM Shriram, Sindhu Trade, Balmer Lawrie, TTK Healthcare, and Panth Infinity, while Average capital structure is found at Empire Inds., and Below Average capital structure is observed at Swan Corp, KCK Industries, and the rest.<BR><BR>Return Snapshot: The peer with the highest 1-year return is 3M India at 18.70%, while the peer with the lowest is DCM Shriram at -24.04%. TTK Healthcare's own 1-year return is -0.14%, which is better than DCM Shriram but worse than 3M India. Additionally, the six-month returns are negative for DCM Shriram, Swan Corp, Balmer Lawrie, and Dhunseri Vent.

How big is TTK Healthcare?

As of 14th August, TTK Healthcare Ltd. has a market capitalization of 1,623.86 Cr, with net sales of 888.41 Cr and a net profit of 73.96 Cr reported in the latest four quarters. The company has shareholder's funds of 1,114.85 Cr and total assets of 1,322.67 Cr as of March 2026.

As of 14th August, TTK Healthcare Ltd. has a market capitalization of 1,623.86 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, TTK Healthcare reported net sales of 888.41 Cr and a net profit of 73.96 Cr.<BR><BR>For the reporting period of March 2026, the company had shareholder's funds amounting to 1,114.85 Cr and total assets of 1,322.67 Cr.

When is the next results date for TTK Healthcare Ltd.?

The next results date for TTK Healthcare Ltd. is 06 August 2026.

The next results date for TTK Healthcare Ltd. is scheduled for 06 August 2026.

Are TTK Healthcare Ltd. latest results good or bad?

TTK Healthcare Ltd.'s latest results show strong revenue growth and a significant profit increase, but declining operating margins and reliance on non-operating income raise concerns about sustainability, making the overall outlook mixed.

TTK Healthcare Ltd.'s latest results present a mixed picture. On the positive side, the company reported a net profit of ₹21.76 crores for Q4 FY26, which is a significant increase of 106.65% quarter-on-quarter and a 34.73% rise year-on-year. Additionally, revenue grew by 14.51% year-on-year to ₹217.98 crores, indicating strong top-line momentum.<BR><BR>However, there are notable concerns regarding the company's operating margins. The operating margin has decreased to 5.06%, down from 6.31% in the same quarter last year, reflecting rising cost pressures that the company has struggled to manage. This decline in margin raises questions about the sustainability of profitability, especially since a substantial portion of the profit before tax, approximately 60.18%, came from other income rather than core operations.<BR><BR>In summary, while TTK Healthcare has shown impressive revenue growth and profit recovery, the deterioration in operating margins and reliance on non-operating income are significant red flags. This combination suggests that the overall results could be viewed as concerning, despite some positive indicators.

Is TTK Healthcare technically bullish or bearish?

As of December 3, 2025, the technical trend has shifted to a moderate bearish stance, driven by bearish MACD readings, Bollinger Bands, and daily moving averages, despite mixed signals from the RSI and KST, with the stock underperforming against the Sensex.

As of 3 December 2025, the technical trend has changed from mildly bearish to bearish. The current stance is bearish with a moderate strength. Key indicators driving this include the bearish MACD readings on both the weekly and monthly time frames, bearish Bollinger Bands, and a bearish daily moving average. The RSI shows no signal on the weekly but is bullish on the monthly, indicating mixed signals. The KST is mildly bullish weekly but bearish monthly, while the OBV is mildly bearish weekly and mildly bullish monthly, adding to the overall bearish sentiment. The stock has underperformed significantly against the Sensex over multiple time frames, further supporting the bearish outlook.

How has been the historical performance of TTK Healthcare?

TTK Healthcare has shown steady growth in net sales and profit from Mar'21 to Mar'25, with net sales increasing from 636.53 Cr to 801.49 Cr and profit before tax rising from 24.84 Cr to 108.33 Cr. However, the company has faced challenges with rising costs and negative cash flow from operating activities.

Answer:<BR>The historical performance of TTK Healthcare shows a steady growth in net sales and profit over the years, with significant fluctuations in certain metrics.<BR><BR>Breakdown:<BR>TTK Healthcare's net sales have increased from 636.53 Cr in Mar'21 to 801.49 Cr in Mar'25, reflecting a consistent upward trend. Total operating income followed a similar trajectory, rising from 645.77 Cr in Mar'20 to 801.49 Cr in Mar'25. The company faced rising raw material costs, which increased from 98.92 Cr in Mar'21 to 195.34 Cr in Mar'25, while the purchase of finished goods also grew from 148.77 Cr to 186.95 Cr in the same period. Operating profit (PBDIT) showed fluctuations, peaking at 106.07 Cr in Mar'25 after a dip in Mar'22. Profit before tax rose significantly from 24.84 Cr in Mar'22 to 108.33 Cr in Mar'25, leading to a profit after tax of 81.66 Cr in Mar'25, up from 18.51 Cr in Mar'22. The company's total assets increased from 427.04 Cr in Mar'20 to 1,275.24 Cr in Mar'25, while total liabilities also rose, reflecting a growth in both equity capital and reserves. Cash flow from operating activities has been negative in recent years, indicating challenges in cash generation, although cash flow from investing activities remained positive. Overall, TTK Healthcare has demonstrated growth in sales and profitability, despite facing challenges with costs and cash flow management.

Is TTK Healthcare overvalued or undervalued?

As of July 28, 2025, TTK Healthcare is considered undervalued with an attractive valuation grade, a PE ratio of 25.50, and competitive financial metrics, making it a potential buying opportunity despite recent underperformance compared to the Sensex.

As of 28 July 2025, TTK Healthcare's valuation grade has moved from fair to attractive, indicating a positive shift in its market perception. The company is currently considered undervalued, with a PE ratio of 25.50, an EV to EBITDA of 29.89, and a Price to Book Value of 1.69. In comparison to its peers, TTK Healthcare's PE ratio is lower than Sun Pharma's 35.57 and Divi's Lab's 79.83, both of which are categorized as expensive, while it is more favorable than Cipla's attractive PE of 23.53.<BR><BR>TTK Healthcare's financial metrics suggest it is positioned well within its industry, especially with a PEG ratio of 2.04, which is competitive against peers like Dr. Reddy's Labs at 9.35. Despite recent stock performance trailing the Sensex, particularly with a year-to-date return of -9.92% compared to the Sensex's 3.52%, the overall valuation indicates that TTK Healthcare presents a buying opportunity for investors looking for growth in the diversified healthcare sector.

Who are the top shareholders of the TTK Healthcare?

The top shareholders of TTK Healthcare are primarily its promoters, with T T Krishnamachari & Co. holding 67.46%. Other notable shareholders include Jupiter India Fund at 1.52% and individual investors with a combined 16.01%.

The top shareholders of TTK Healthcare are primarily its promoters, with T T Krishnamachari & Co. holding the largest share at 67.46%, represented by its partners Mr. T T Jagannathan and Mr. T T Raghunathan. Other notable shareholders include Jupiter India Fund, which holds 1.52%, and individual investors collectively owning 16.01%. Additionally, there are four mutual fund schemes that hold a combined 0.04%, and nine foreign institutional investors (FIIs) with a total holding of 1.89%.

Has TTK Healthcare declared dividend?

TTK Healthcare Ltd. has declared a 100% dividend, amounting to ₹10 per share, with an ex-date of July 16, 2024. While the recent total returns show declines in the short term, the company has experienced significant growth over the longer term.

TTK Healthcare Ltd. has declared a 100% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 100%<BR>- Amount per share: 10<BR>- Ex-date: 16 Jul 24<BR><BR>Dividend Yield: 0.81%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was -21.3%, the dividend return was 0%, resulting in a total return of -21.3%.<BR><BR>Over the past year, the price return was -14.86%, the dividend return was 0.66%, leading to a total return of -14.2%.<BR><BR>In the 2-year period, the price return was -3.25%, the dividend return was 1.58%, culminating in a total return of -1.67%.<BR><BR>For the 3-year period, the price return was 66.56%, the dividend return was 4.22%, resulting in a total return of 70.78%.<BR><BR>In the last 4 years, the price return was 81.28%, the dividend return was 5.44%, which brought the total return to 86.72%.<BR><BR>Over the past 5 years, the price return was 187.39%, the dividend return was 8.95%, leading to a total return of 196.34%.<BR><BR>Overall, TTK Healthcare has declared a substantial dividend, but the recent total returns indicate a mixed performance, with significant growth over the longer term despite recent declines in shorter periods.